ClinicalTrials.gg
Not yet recruitingNCT05602168Updated Nov 1, 2022

Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance

An interventional study of experimental:Acute leukemia/myelodysplastic or myeloproliferative disease in Hematologic Cancer, sponsored by Institut Paoli-Calmettes. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by Institut Paoli-Calmettes · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes — 4 open to participants now, 4 under way, none of them phase 3. Hematologic Neoplasms · Institut Paoli-Calmettes.

Started
2023
the only one that year
No phase
3 of 10
2 open now
Registered
8th of 10
by date

Among the 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes, this one is the only one that started in 2023, is one of 3 with no phase, and was the 8th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

4 of the 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hematologic Neoplasms by Institut Paoli-Calmettes, or all of them as a file.
02

Study summary

The main objective is to study the genomic, transcriptomic, proteomic epigenomic, metabolomic and immune mechanisms of blasts and microenvironment cells associated with IT resistance through the constitution of a collection associating blood or marrow samples from patients with LA, MDS and MPS marrow samples from patients with LA, MDS and MPS at diagnosis, during treatment and at relapse and relapse and clinical annotations.

Read the detailed description

It is a collection of blood, marrow and oral epithelial cell samples taken longitudinally and oral epithelial cells taken longitudinally for each patient included, with each patient included, with the corresponding clinical data. An oral epithelial cell sample will be collected at inclusion from 2 swabs, which will allow extraction of DNA from healthy from healthy cells. During blood sampling necessary for care, an additional 40 ml of blood will be collected of 40 ml of blood will be collected in 10 tubes of 4 ml: 4 EDTA tubes, 4 heparinized heparinized tubes and 2 dry tubes. These additional collections will take place at the following times:

  • At inclusion
  • 7 days (+/- 2 days) after initiation of treatment
  • 14 days (+/- 2 days) after initiation of therapy
  • 21-42 days after initiation of therapy (early response assessment)
  • In case of complete remission
  • In case of relapse or progression During bone marrow punctures required for treatment, 6 ml of bone marrow bone marrow will be collected in 2 tubes of 3 ml: 1 EDTA tube and 1 heparinized tube.

heparinized tube. These additional collections will take place at the following times following times:

  • At inclusion
  • 21-42 days after initiation of treatment (assessment of early response) early response)
  • In case of complete remission
  • In case of relapse or progression Patients will be followed for up to 2 years after inclusion.
03

Conditions studied

  • Hematologic Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of acute leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia (CMML) or myeloproliferative syndrome according to the WHO classification 2016,
  2. Patient for whom a new is initiated.
  3. Patient older than 18 years of age.
  4. Patient affiliated to the social security system or benefiting from such a system.
  5. Signed consent to participate.

Exclusion criteria

Exclusion Criteria:

  1. Weight at inclusion \< 50 kg
  2. Participating in another clinical study that would cause the total amount of blood collection to exceed the and endanger the patient
  3. Person in an emergency situation, adult under legal protection (guardianship, curatorship, etc.) protection (guardianship, curatorship or safeguard of justice), or unable to express his or her consent.
  4. Impossibility to submit to the medical follow-up of the trial for geographical social or psychological reasons,
  5. Pregnant or breastfeeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    experimental:Acute leukemia/myelodysplastic or myeloproliferative disease

    blood sampling, bone marrow aspirate, and buccal swab

    Other: experimental:Acute leukemia/myelodysplastic or myeloproliferative disease

Interventions

  • Otherexperimental:Acute leukemia/myelodysplastic or myeloproliferative disease

    blood sampling, bone marrow aspirate and buccal swab

06

What researchers measure

Primary outcomes

  1. Acute leukemia/ Myeloproliferative/ myelodysplastic syndrome cells profiling (molecular analysis, epigenetic profile, drug sensitivity profile,immunophenotyping)

    establishment of genomic and proteomic signatures as well as transcriptomic and metabolic profiles associated with IT resistance.

    Time frame: up to 7 years

Secondary outcomes

  1. to study the resistance to treatments

    study of the sensitivity to IT in vitro of primary cells from patients

    Time frame: up to 7 years

  2. Creation of murine cell models (Patient-derived xenografts, PDX) from patient blasts to study in vivo in order to study in vivo the mechanisms of resistance to treatment.

    Establishment of xenografts in immunocompromised mice from primary cells of TI-resistant patients patients resistant to IT

    Time frame: up to 7 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2023; primary completion for Jan 2030, 84 months later.

Of 186 non-industry interventional studies with no phase under Hematologic Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 125. This study's planned 84 months is above that.

Counting every sponsor, half of 192 studies reached it within 40 months; a quarter within 21 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2022
First posted
Nov 1, 2022
StartEst.
Jan 2023
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2030
Last update
Nov 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05602168
Responsible party
Sponsor
First posted
Nov 1, 2022
Start date
Jan 2023 (estimated)
Primary completion
Jan 2030 (estimated)
Completion
Jan 2030 (estimated)
Last update
Nov 1, 2022

Study contacts

Dominique GENRE, MD
Contact
drci.up@ipc.unicancer.fr
+33491223778

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion